Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. - Wikidata - awgldk - TriplyDB

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

http://www.wikidata.org/entity/Q48793112

about

Laquinimod for multiple sclerosis Laquinimod for multiple sclerosis Laquinimod in the treatment of multiple sclerosis: a review of the data so far The role of neurotrophins in multiple sclerosis-pathological and clinical implications Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.Laquinimod therapy in multiple sclerosis: a comprehensive review Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity Therapeutic decisions in multiple sclerosis: moving beyond efficacy Efficacy and safety of laquinimod in multiple sclerosis: current status Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis.Laquinimod in the treatment of relapsing remitting multiple sclerosis.Primary Progressive Multiple Sclerosis: Putting Together the Puzzle Experimental Autoimmune Encephalomyelitis (EAE)-Induced Elevated Expression of the E1 Isoform of Methyl CpG Binding Protein 2 (MeCP2E1): Implications in Multiple Sclerosis (MS)-Induced Neurological Disability and Associated Myelin Damage Defining a role for laquinimod in multiple sclerosis.Laquinimod treatment in the R6/2 mouse model.Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study.Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination.Excitotoxins, Mitochondrial and Redox Disturbances in Multiple Sclerosis.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models.Drugs in development for relapsing multiple sclerosis.Advancing therapeutic options in multiple sclerosis with neuroprotective properties.Neuroprotection in multiple sclerosis: a therapeutic approach.Review of laquinimod and its therapeutic potential in multiple sclerosis.Established and novel disease-modifying treatments in multiple sclerosis.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

P2860

Q24198180-54A00923-CDD2-4324-B8C5-FBB816FF65E2 Q24200527-06381010-E91E-4C3E-BF65-A86A4980A1D8 Q26752895-ADCFAA9B-2028-4103-8D49-3BBC631D9CBF Q26849274-4813EA00-5719-4A06-AE88-C956DA84D8BA Q26999417-F7ED6113-E541-459D-B9C6-CD0B526072C2 Q27011473-3CA62B28-B462-41D8-BEA1-5FB21B296B81 Q27316866-6E0D0D77-6D52-47E4-BC39-42C4DFBA91BA Q28086844-B720711D-BEB6-4EBB-BAF1-D88E38A7629C Q28481922-3CBA615F-2C69-4209-9965-88DC6BBEA085 Q28541039-E4B547BD-CEBB-4F86-9042-316833DD7E4B Q30694702-C748E47C-B4DD-44B1-B7AD-E6EA95A481A7 Q30869048-F75B99E6-BC58-4B6C-A71B-B67E8BB0FD69 Q30965003-BDD87B94-9EAD-4676-9328-125450937E31 Q31017620-AEE2D757-F27E-462A-8B33-AA76CF001AD5 Q31080085-6B5B4E72-3E35-4C7D-885B-6DAA002430A5 Q33365606-63D5EEF1-B766-408C-8542-2D1470D34820 Q33838894-9ADC136D-728F-4ACA-8B7B-C8CEF7413FD1 Q33847350-7D454BA2-107C-42B1-B517-A09AF1B589F1 Q33890346-C3851767-E43A-4DE0-A22A-58DA1A402AC5 Q33988247-3BA5B887-F795-4A19-99E2-E31168D60E46 Q34332609-0E09B018-2616-4549-8750-E1FE0E50313E Q35542637-02AA2881-E4B7-4335-BC00-3B8F5E686703 Q35648000-55EA248D-31E8-42B9-9079-0F379E34AC08 Q36174480-4307A589-040E-4635-8F5F-81B2394487C7 Q36283207-F1715CB6-DB23-4544-9F50-31A3474193E3 Q36396476-22A2CB15-EE97-42EA-BF11-3D074FBA7BDA Q36648175-767421C6-55B0-4C5D-81EB-F9180C893A7E Q37274895-97518A7A-2B42-4AFA-9CC4-8DA53A9C3971 Q37346761-8B390209-6766-4EB7-AE6B-28B578C712E3 Q37403700-0602C32C-B172-47AD-8A6E-E3E5EF3412B1 Q37603419-E8226BBD-B037-4C11-880D-AD0A33CC7F0E Q38018673-B9D867EE-353C-4B77-84D7-EB5ED810CD20 Q38071242-728EB609-3C5F-42E0-BE06-66246A099B6D Q38101004-BCB74349-C721-4479-B93B-219BEAEE5DE3 Q38110475-FE2042BC-4751-4D76-845C-F23B76E90091 Q38129748-D4DF997F-0498-4D24-895F-B23AB38602BA Q38161575-CDE70EBD-8E8F-46BB-89B1-EAF16FADE6BB Q38180157-3CA20A52-1352-42A2-867C-8D0C10F48673 Q38186206-BC823BEA-4258-4393-95C7-AB0B1E829433 Q38196701-089DA91D-3052-433A-9AE1-6E0027F46F05

P2860

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.

http://www.wikidata.org/entity/Q48793112

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@en

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@nl

type

label

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@en

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@nl

prefLabel

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@en

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@nl

P1433

Q48793112-3F88A456-13C1-4AD5-BAC1-C934C00181BF

P1476

Q48793112-28DF8AB3-CD56-4434-AD80-7083396E67B3

P2093

Q48793112-02351E1C-C01F-4A9C-A81B-6DBEE212524E

Q48793112-0D1D5BA3-FE34-4795-A18B-E547618D89B4

Q48793112-25A3D113-304D-4912-96D6-1E5195D46EC3

Q48793112-4091D62F-16E1-48DF-91EA-4476615FC9DC

Q48793112-518403F7-6D33-4A57-AAFD-B1E5DBB16A3B

Q48793112-7C761C8F-3347-48A7-959E-5FCC09727662

Q48793112-9E309F44-4AEF-45B3-B951-082FD07967DA

Q48793112-AE899428-4D95-4B5E-83E2-8A01C86FD233

Q48793112-C1FF7C01-6350-4781-90E1-55F6DB3B2E27

Q48793112-CA76B70E-C382-4D6D-BED3-8C5413C3C11E

P304

Q48793112-93D3924F-1263-4CD3-8631-AD6F64765591

P31

Q48793112-530E6B56-DEC2-4B7D-A02E-89B4605FCB21

P356

Q48793112-5464AEC4-3F93-40A8-A2BE-D1C2C820AABC

P407

Q48793112-2FCFD89C-764C-4B7F-8399-6735DB35ECC0

P433

Q48793112-E385755F-C5A5-4E68-83F8-42F28EF15528

P478

Q48793112-F0A0E24E-BB30-4014-8A23-50A68BF65006

P50

Q48793112-6D33C6BF-0DD0-4717-B001-3C9CB745E337

P577

Q48793112-CC882347-E853-49B5-99E9-C5C17A929F15

P5875

Q48793112-95B2699F-E424-4242-96C6-B8E7253AABF7

P698

Q48793112-43BBA618-C565-4CF6-88C7-C285515AAFB7

P356

J.AJPATH.2011.09.037

P1433

The American Journal of Pathology

P1476

Modulation of autoimmune demye ...... n-derived neurotrophic factor.

@en

P2093

De-Hyung Lee

http://www.w3.org/2001/XMLSchema#string

Gisa Ellrichmann

http://www.w3.org/2001/XMLSchema#string

Isabella Peruga

http://www.w3.org/2001/XMLSchema#string

Jan Thöne

http://www.w3.org/2001/XMLSchema#string

Liat Hayardeny

http://www.w3.org/2001/XMLSchema#string

Ralf A Linker

http://www.w3.org/2001/XMLSchema#string

Ralf Gold

http://www.w3.org/2001/XMLSchema#string

Rebecca Conrad

http://www.w3.org/2001/XMLSchema#string

Silvia Seubert

http://www.w3.org/2001/XMLSchema#string

Stefan Wiese

http://www.w3.org/2001/XMLSchema#string

P304

267-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2011.09.037

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51863209

http://www.w3.org/2001/XMLSchema#string

P698

22152994

http://www.w3.org/2001/XMLSchema#string